Abstract
As conventional therapeutics can only treat the symptoms of Parkinson’s disease (PD), major focus of research in recent times is to slow down or prevent the progression of neuronal degeneration in PD. Non-targeted antioxidants have been an integral part of the conventional therapeutics regimen; however, their importance have lessened over time because of their controversial outcomes in clinical PD trials. Inability to permeate and localize within the mitochondria remains the main drawback on the part of non-targeted antioxidants inspite of possessing free radical scavenging properties. In contrast, mitochondrial-targeted antioxidants (MTAs), a special class of compounds have emerged having high advantages over non-targeted antioxidants by virtue of efficient pharmacokinetics and better absorption rate with capability to localize many fold inside the mitochondrial matrix. Preclinical experimentations indicate that MTAs have the potential to act as better alternatives compared to conventional non-targeted antioxidants in treating PD; however, sufficient clinical trials have not been conducted to investigate the efficacies of MTAs in treating PD. Controversial clinical outcomes on the part of non-targeted antioxidants and lack of clinical trials involving MTAs have made it difficult to go ahead with a direct comparison and in turn have slowed down the progress of development of safer and better alternate strategies in treating PD. This review provides an insight on the roles MTAs and non-targeted antioxidants have played in the treatment of PD till date in preclinical and clinical settings and discusses about the limitations of mitochondria-targeted and non-targeted antioxidants that can be resolved for developing effective strategies in treating Parkinsonism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdel-Salam OM (2008) Drugs used to treat Parkinson’s disease, present status and future directions. CNS Neurol Disorder Drug Targets 7:321–342. https://doi.org/10.2174/187152708786441867
Agapova LS, Chernyak BV, Domnina LV, Dugina VB, Efimenko AY, Fetisova EK et al (2008) Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells. Biochemistry (mosc) 73:1300–1316. https://doi.org/10.1134/s0006297908120031
Allen J, Bradley RD (2011) Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med 17:827–833. https://doi.org/10.1089/acm.2010.0716
Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78:6858–6862. https://doi.org/10.1073/pnas.78.11.6858
Anantharam V, Kaul S, Song C, Kanthasamy A, Kanthasamy AG (2007) Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology 28:988–997. https://doi.org/10.1016/j.neuro.2007.08.008
Andres RH, Huber AW, Schlattner U, Perez-Bouza A, Krebs SH, Seiler RW, Wallimann T, Widmer HR (2005) Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. Neuroscience 133:701–713. https://doi.org/10.1016/j.neuroscience.2005.03.004
Anisimov VN, Bakeeva LE, Egormin PA, Filenko OF, Isakova EF, Manskikh VN et al (2008) Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 5. SkQ1 prolongs lifespan and prevents development of traits of senescence. Biochemistry (mosc) 73:1329–1342. https://doi.org/10.1134/s0006297908120055
Antonenko YN, Avetisyan AV, Bakeeva LE, Chernyak BV, Chertkov VA, Domnina LV et al (2008) Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: synthesis and in vitro studies. Biochemistry (mosc) 73:1273–1287. https://doi.org/10.1134/s0006297908120018
Aryal S, Skinner T, Bridges B, Weber JT (2020) The pathology of Parkinson’s disease and potential benefit of dietary polyphenols. Molecules 25:4382. https://doi.org/10.3390/molecules25194382
Bagga V, Dunnett SB, Fricker-Gates RA (2008) Ascorbic acid increases the number of dopamine neurons in vitro and in transplants to the 6-OHDA-lesioned rat brain. Cell Transplant 17:763–773. https://doi.org/10.3727/096368908786516774
Bakeeva LE, Barskov IV, Egorov MV, Isaev NK, Kapelko VI, Kazachenko AV et al (2008) Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 2. Treatment of some ROS- and age-related diseases (heart arrhythmia, heart infarctions, kidney ischemia, and stroke). Biochemistry (mosc) 73:1288–1299. https://doi.org/10.1134/s000629790812002x
Barc S, Page G, Barrier L, Huguet F, Fauconneau B (2002) Progressive alteration of neuronal dopamine transporter activity in a rat injured by an intranigral injection of MPP+. Brain Res 941:72–81. https://doi.org/10.1016/s0006-8993(02)02567-2
Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R et al (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71:543–552. https://doi.org/10.1001/jamaneurol.2014.131
Beal MF, Matthews RT (1997) Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol Aspects Med 18(Suppl):S169–S179. https://doi.org/10.1016/s0098-2997(97)00024-1
Beal MF, Matthews RT, Tieleman A, Shults CW (1998) Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 783:109–114. https://doi.org/10.1016/s0006-8993(97)01192-x
Becker BF (1993) Towards the physiological function of uric acid. Free Radic Biol Med 14:615–631. https://doi.org/10.1016/0891-5849(93)90143-i
Bermúdez ML, Seroogy SB, Genter MB (2019) Evaluation of carnosine intervention in the Thy1-aSyn mouse model of Parkinson’s disease. Neuroscience 411:270–278. https://doi.org/10.1016/j.neuroscience.2019.05.026
Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA (2016) Oral inosine persistently elevates plasma antioxidant capacity in Parkinson’s disease. Mov Disord 31:417–421. https://doi.org/10.1002/mds.26483
Boldyrev A, Fedorova T, Stepanova M, Dobrotvorskaya I, Kozlova E, Boldanova N et al (2008) Carnosine increases efficiency of DOPA therapy of Parkinson’s disease: a pilot study. Rejuvenation Res 11:821–827. https://doi.org/10.1089/rej.2008.0716
Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211. https://doi.org/10.1016/s0197-4580(02)00065-9
Brenza TM, Ghaisas S, Ramirez JEV, Harischandra D, Anantharam V, Kalyanaraman B et al (2017) Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy. Nanomedicine Nanotechnology Biol Med 13:809–820. https://doi.org/10.1016/j.nano.2016.10.004
Broen MPG, Narayen NE, Kuijf ML et al (2016) Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 31:1125–1133. https://doi.org/10.1002/MDS.26643
Castillo S, Muñoz P, Behrens MI et al (2017) On the Role of mining exposure in epigenetic effects in Parkinson’s disease. Neurotox Res 32:172–174. https://doi.org/10.1007/S12640-017-9736-7
Cerri S, Mus L, Blandini F (2019) Parkinson’s disease in women and men: what’s the difference?. J Parkinsons Dis 9:501–515. https://doi.org/10.3233/JPD-191683
Chen H, Mosley TH, Alonso A, Huang X (2009) Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 169:1064–1069. https://doi.org/10.1093/aje/kwp033
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277–1281. https://doi.org/10.1016/S0140-6736(04)16000-5
Chou KL, Taylor JL, Patil PG (2013) The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease. Parkinsonism Relat Disord 19(11):966–969. https://doi.org/10.1016/j.parkreldis.2013.06.010
Cipriani S, Bakshi R, Schwarzschild MA (2014) Protection by inosine in a cellular model of Parkinson’s disease. Neuroscience 22(274):242–249. https://doi.org/10.1016/j.neuroscience.2014.05.038
Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, Beal MF (2008) Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 104:1613–1621. https://doi.org/10.1111/j.1471-4159.2007.05097.x
Cohen AM, Aberdroth RE, Hochstein P (1984) Inhibition of free radical-induced DNA damage by uric acid. FEBS Lett 174:147–150. https://doi.org/10.1016/0014-5793(84)81094-7
Coles LD, Tuite PJ, Öz G, Mishra UR, Kartha RV, Sullivan KM, Cloyd JC, Terpstra M (2018) Repeated-dose oral NAcetylcysteine in Parkinson’s disease: pharmacokinetics and effect on brain glutathione and oxidative stress. J Clin Pharmacol 58:158–167. https://doi.org/10.1002/jcph.1008
Colombo ML (2010) An update on vitamin E, tocopherol and tocotrienol-perspectives. Molecules 15:2103–2113. https://doi.org/10.3390/molecules15042103
Crane FL (2001) Biochemical functions of coenzyme Q10. J Am Coll Nutr 20:591–598. https://doi.org/10.1080/07315724.2001.10719063
Das B, Dash SP, Mohanty S, Patel P (2021a) Parkinson’s disease and impairment in mitochondrial metabolism: a pathognomic signature. Adv Exp Med Biol 1286:65–76. https://doi.org/10.1007/978-3-030-55035-6_4
Das B, Ray P, Raut S (2021b) Impaired mitochondrial energy metabolism: etiologies and implications in neurodegenerative disease. In: Ostojic SM (ed) Clinical Bioenergetics: From pathophysiology to clinical translation, 1st edn. Academic Press, London, pp 93–118
Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM (1996) Observations on serumuric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol 144:480–484. https://doi.org/10.1093/oxfordjournals.aje.a008954
Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P (1986) Uric acid–iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235:747–754. https://doi.org/10.1042/bj2350747
de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005) Serumuric acid levels and therisk of Parkinson disease. Ann Neurol 58:797–800. https://doi.org/10.1002/ana.20663
Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, Joseph J, Kalyanaraman B (2004) Supplementation of endothelial cells with mitochondria targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem 279:37575–37587. https://doi.org/10.1074/jbc.M404003200
Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI (2010) Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 107:106–116. https://doi.org/10.1161/CIRCRESAHA.109.214601
Dahodwala N, Shah K, He Y et al (2018) Sex disparities in access to caregiving in Parkinson disease. Neurology 90:E48–E54. https://doi.org/10.1212/WNL.0000000000004764
Doughan AK, Dikalov SI (2007) Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis. Antioxid Redox Signal 9:1825–1836. https://doi.org/10.1089/ars.2007.1693
Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG, Kalyanaraman B (2013) Diapocynin prevents early Parkinson’s disease symptoms in the leucine-rich repeat kinase 2 (LRRK2) transgenic mouse. Neurosci Lett 549:57–62. https://doi.org/10.1016/j.neulet.2013.05.034
Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 80:101–110. https://doi.org/10.1046/j.0022-3042.2001.00676.x
Duarte-Jurado AP, Gopar-Cuevas Y, Saucedo-Cardenas O, Loera-Arias MDJ, Montes-de-Oca-Luna R, Garcia-Garcia A, Rodriguez-Rocha H (2021) Antioxidant therapeutics in Parkinson’s disease: current challenges and opportunities. Antioxidants 10:453. https://doi.org/10.3390/antiox10030453
Elfawy HA, Das B (2019) Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: etiologies and therapeutic strategies. Life Sci 218:165–184. https://doi.org/10.1016/j.lfs.2018.12.029
El-Shamarka MEA, Kozman MR, Messiha BAS (2020) The protective effect of inosine against rotenone-induced Parkinson’s disease in mice; role of oxido-nitrosative stress, ERK phosphorylation, and A2AR expression. Naunyn Schmiedebergs Arch Pharmacol 393(6):1041–1053. https://doi.org/10.1007/s00210-019-01804-1
Etminan M, Gill SS, Samii A (2005) Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol 4:362–365. https://doi.org/10.1016/S1474-4422(05)70097-1
Ernster L, Dallner G (1995) Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271:195–204. https://doi.org/10.1016/0925-4439(95)00028-3
Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 32: S128–S132(Suppl.). https://doi.org/10.1002/ana.410320722
Fernández-Checa JC, Kaplowitz N, García-Ruiz C, Colell A (1998) Mitochondrial glutathione: importance and transport. Semin Liver Dis 18:389–401. https://doi.org/10.1055/s-2007-1007172
Filipovska A, Kelso GF, Brown SE, Beer SM, Smith RA, Murphy MP (2005) Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic. Insights into the interaction of ebselen with mitochondria. J Biol Chem 280:24113–24126. https://doi.org/10.1074/jbc.M501148200
Galpern WR, Cudkowicz ME (2007) Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion 7(Suppl.):S146–S153. https://doi.org/10.1016/j.mito.2007.01.004
Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, Murphy MP (2010) The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 30:1019–1026. https://doi.org/10.1111/j.1478-3231.2010.02250.x
Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CE, Kanthasamy A, Kanthasamy A, Kalyanaraman B (2010) Neuroprotection by a mitochondria targeted drug in a Parkinson’s disease model. Free Radic Biol Med 49:1674–1684. https://doi.org/10.1016/j.freeradbiomed.2010.08.028
Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG (2012) Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinicalmodels of Parkinson’s disease. J Neuroinflammation 9:241. https://doi.org/10.1186/1742-2094-9-241
Ghosh A, Langley MR, Harischandra DS, Neal ML, Jin H, Anantharam V, Joseph J, Brenza T, Narasimhan B, Kanthasamy A, Kalyanaraman B, Kanthasamy AG (2016) Mitoapocynin treatment protects against neuroinflammation and dopaminergic neurodegeneration in a preclinical animal model of Parkinson’s disease. J Neuroimmune Pharmacol 11(2):259–278. https://doi.org/10.1007/s11481-016-9650-4
Gille G, Hung ST, Reichmann H, Rausch WD (2004) Oxidative stress to dopaminergic neurons as models of Parkinson’s disease. Ann N Y Acad Sci 1018:533–540. https://doi.org/10.1196/annals.1296.066
Gong L, Daigneault EA, Acuff RV, Kostrzewa RM (1991) Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. NeuroReport 2:544–546. https://doi.org/10.1097/00001756-199109000-00012
Gualano B, de Salles PV, Roschel H, Lugaresi R, Dorea E, Artioli GG et al (2010) Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. Eur J Appl Physiol 111:749–756. https://doi.org/10.1007/s00421-010-1676-3
Guerreiro S, Ponceau A, Toulorge D, Martin E, Alvarez-Fischer D, Hirsch EC, Michel PP (2009) Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem 109:1118–1128. https://doi.org/10.1111/j.1471-4159.2009.06040.x
Gunnarsson LG, Bodin L (2017) Parkinson’s disease and occupational exposures: a systematic literature review and meta-analyses. Scand J Work Environ Health 43:197–209. https://doi.org/10.5271/SJWEH.3641
Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D (2009) Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord 24:979–983. https://doi.org/10.1002/mds.22401
Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, Öz G et al (2013) N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 36:103–106. https://doi.org/10.1097/WNF.0b013e31829ae713
Horvath TL, Diano S, Leranth C, Garcia-Segura LM, Cowley MA, Shanabrough M et al (2003) Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson’s disease. Endocrinology 144:2757–2760. https://doi.org/10.1210/en.2003-0163
Hou L, Sun F, Huang R, Sun W, Zhang D, Wang Q (2019) Inhibition of NADPH oxidase by apocynin prevents learning and memory deficits in a mouse Parkinson’s disease model. Redox Biol 22:101134. https://doi.org/10.1016/j.redox.2019.101134
Hughes G, Murphy MP, Ledgerwood EC (2005) Mitochondrial reactive oxygen species regulate the temporal activation of nuclear factor kappaB to modulate tumour necrosis factor-induced apoptosis: evidence from mitochondria-targeted antioxidants. Biochem J 389:83–89. https://doi.org/10.1042/BJ20050078
Hughes KC, Gao X, Kim IY, Rimm EB, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A (2016) Intake of antioxidant vitamins and risk of Parkinson’s disease. Mov Disord 31:1909–1914. https://doi.org/10.1002/mds.26819
Investigators NN-PD (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664–671. https://doi.org/10.1212/01.wnl.0000201252.57661.e1
Ikram M, Park TJ, Ali T, Kim MO (2020) Antioxidant and neuroprotective effects of caffeine against Alzheimer’s and Parkinson’s disease: insight into the role of Nrf-2 and A2AR signaling. Antioxidants 9:902. https://doi.org/10.3390/antiox9090902
Investigators NN-PD (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31:141–150. https://doi.org/10.1097/WNF.0b013e3181342f32
Jankovic J, Stacy M (2007) Medicalmanagement of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs 21:677–692. https://doi.org/10.2165/00023210-200721080-00005
Jauslin ML, Meier T, Smith RA, Murphy MP (2003) Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 17:1972–1974. https://doi.org/10.1096/fj.03-0240fje
Jiang Q, Yin J, Chen J, Ma X, Wu M, Liu G, Yao K, Tan B, Yin Y (2020) mitochondria-targeted antioxidants: a step towards disease treatment. Oxid Med Cell Longev 3(2020):8837893. https://doi.org/10.1155/2020/8837893
Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG (2014) Mitochondria targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes. Biochem Biophys Acta 1842(8):1282–1294. https://doi.org/10.1016/j.bbadis.2013.09.007
Johnson DK, Schillinger KJ, Kwait DM et al (2002) Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium 9(3):191–203. https://doi.org/10.1080/10623320213638
Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2009) Parkinson disease: extranigral, multisystem, and alpha-synuclein “plus.” Arch Neurol 66:914–915. https://doi.org/10.1001/archneurol.2009.140
Kanegae MP, Condino-Neto A, Pedroza LA, de Almeida AC, Rehder J, da Fonseca LM, Ximenes VF (2010) Diapocynin versus apocynin as pretranscriptional inhibitors of NADPH oxidase and cytokine production by peripheral blood mononuclear cells. Biochem Biophys Res Commun 393:551–554. https://doi.org/10.1016/j.bbrc.2010.02.073
Kelso GF, Maroz A, Cocheme HM, Logan A, Prime TA, Peskin AV et al (2012) A mitochondria-targeted macrocyclic Mn(II) superoxide dismutase mimetic. Chem Biol 19:1237–1246. https://doi.org/10.1016/j.chembiol.2012.08.005
Kirik D, Rosenblad C, Bjorklund A (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152:259–277. https://doi.org/10.1006/exnr.1998.6848
Kizhakekuttu TJ, Wang J, Dharmashankar K, Ying R, Gutterman DD, Vita JA, Widlansky ME (2012) Adverse alterations in mitochondrial function contribute to type 2 diabetes mellitus-related endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 32:2531–2539. https://doi.org/10.1161/ATVBAHA.112.256024
Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E et al (2000) Mice deficient in cellular glutathione peroxidise show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J Neurosci 20:1–7. https://doi.org/10.1523/JNEUROSCI.20-01-00001.2000
Knaryan VH, Samantaray S, Le Gal C, Ray SK, Banik NL (2011) Tracking extranigral degeneration in animal models of Parkinson’s disease: quest for effective therapeutic strategies. J Neurochem 118:326–338. https://doi.org/10.1111/j.1471-4159.2011.07320.x
Kohen R, Yamamoto Y, Cundy KC, Ames BN (1988) Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci USA 85:3175–3179. https://doi.org/10.1073/pnas.85.9.3175
Kubota M, Kobayashi N, Sugizaki T, Shimoda M, Kawahara M, Tanaka KI (2020) Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson’s disease. PLoS ONE 15:e0240448. https://doi.org/10.1371/journal.pone.0240448
Lan J, Jiang DH (1997) Desferrioxamine and vitamin E protect against iron and MPTP induced neurodegeneration in mice. J Neural Transm 104:469–481. https://doi.org/10.1007/BF01277665
Lawler JM, Barnes WS, Wu G, Song W, Demaree S (2002) Direct antioxidant properties of creatine. Biochem Biophys Res Commun 290:47–52. https://doi.org/10.1006/bbrc.2001.6164
Lee HB, Schwab TL, Sigafoos AN et al (2019) Novel zebrafish behavioral assay to identify modifiers of the rapid, nongenomic stress response. Genes Brain Behav 18(2):e12549. https://doi.org/10.1111/gbb.12549
LeWitt PA (1994) Clinical trials of neuroprotection in Parkinson’s disease: long-term selegiline and alpha-tocopherol treatment. J Neural Transm Suppl 43:171–181. https://pubmed.ncbi.nlm.nih.gov/7884399/
Lewitt PA (2008) Levodopa for the treatment of Parkinson’s disease. N Engl J Med 359:2468–2476. https://doi.org/10.1056/NEJMct0800326
Liang HL, Sedlic F, Bosnjak Z, Nilakantan V (2010) SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery. Free Radic Biol Med 49:1550–1560. https://doi.org/10.1016/j.freeradbiomed.2010.08.018
Liberman EA, Topaly VP, Tsofina LM, Jasaitis AA, Skulachev VP (1969) Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature 222:1076–1078. https://doi.org/10.1038/2221076a0
Lim S, Rashid MA, Jang M, Kim Y, Won H, Lee J, Woo JT, Kim YS, Murphy MP, Ali L, Ha J, Kim SS (2011) Mitochondria-targeted antioxidants protect pancreatic beta-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity. Cell Physiol Biochem 28:873–886. https://doi.org/10.1159/000335802
Luchtefeld R, Luo R, Stine K, Alt ML, Chernovitz PA, Smith RE (2008) Dose formulation and analysis of diapocynin. J Agric Food Chem 56:301–306. https://doi.org/10.1021/jf072792n
Man Anh H, Linh DM, My Dung V, Thi Phuong Thao D (2019) Evaluating dose- and time-dependent effects of vitamin C treatment on a Parkinson’s disease fly model. Parkinsons Dis 2019:9720546. https://doi.org/10.1155/2019/9720546
Mandemakers W, Morais VA, De Strooper B (2007) A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J Cell Sci 120:1707–1716. https://doi.org/10.1242/jcs.03443
Martinovits G, Melamed E, Cohen O, Rosenthal J, Uzzan A (1986) Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). Neurosci Lett 69:192–197. https://doi.org/10.1016/0304-3940(86)90602-6
McInnes J (2013) Insights on altered mitochondrial function and dynamics in the pathogenesis of neurodegeneration. Transl Neurodegener 2:12. https://doi.org/10.1186/2047-9158-2-12
Medina S, Martínez M, Hernanz A (2002) Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1–42. Free Radic Res 36:1179–1184. https://doi.org/10.1080/107157602100006445
Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G et al (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157:142–149. https://doi.org/10.1006/exnr.1999.7049
Mischley LK, Vespignani MF, Finnell JS (2013) Safety survey of intranasal glutathione. J Altern Complement Med 19:459–463. https://doi.org/10.1089/acm.2011.0673
Mischley LK, Leverenz JB, Lau RC, Polissar NL, Neradilek MB, Samii A, Standish LJ (2015) A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson’s disease. Mov Disord 30:1696–1701. https://doi.org/10.1002/mds.26351
Mizuno Y, Hattori N, Mori H, Suzuki T, Tanaka K (2001) Parkin and Parkinson’s disease. Curr Opin Neurol 14:477–482. https://doi.org/10.1097/00019052-200108000-00008
Moisan F, Kab S, Mohamed F et al (2016) Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry 87:952–957. https://doi.org/10.1136/JNNP-2015-312283
Moon Y, Lee KH, Park JH, Geum D, Kim K (2005) Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J Neurochem 93:1199–1208. https://doi.org/10.1111/j.1471-4159.2005.03112.x
Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR (1996) Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology 46:1270–1274. https://doi.org/10.1212/wnl.46.5.1270
Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Bazzan AJ et al (2019) N-Acetyl cysteine is associated with dopaminergic improvement in Parkinson’s disease. Clin Pharmacol Ther 106:884–890. https://doi.org/10.1002/cpt.1548
Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Cai J et al (2016) N-Acetyl cysteine may support dopamine neurons in Parkinson’s disease: preliminary clinical and cell line data. PLoS ONE 11:e0157602. https://doi.org/10.1371/journal.pone.0157602
Murphy MP, Echtay KS, Blaikie FH, Asin-Cayuela J, Cocheme HM, Green K et al (2003) Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from alpha-phenyl-N-tertbutylnitrone. J Biol Chem 278:48534–48545. https://doi.org/10.1074/jbc.M308529200
Murphy MP, Smith RA (2007) Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47:629–656. https://doi.org/10.1146/annurev.pharmtox.47.120505.105110
Mursaleen L, Noble B, Chan SHY, Somavarapu S, Zariwala MG (2020) N-Acetylcysteine nanocarriers protect against oxidative stress in a cellular model of Parkinson’s disease. Antioxidants 9(7):600. https://doi.org/10.3390/antiox9070600
Nagayama H, Hamamoto M, Ueda M, Nito C, Yamaguchi H, Katayama Y (2004) The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol 27:270–273. https://doi.org/10.1097/01.wnf.0000150865.21759.bc
Negida A, Menshawy A, El Ashal G, Elfouly Y, Hani Y, Hegazy Y et al (2016) Coenzyme Q10 for patients with Parkinson’s disease: a systematic review and meta-analysis. CNS Neurol Disord Drug Targets 15:45–53. https://doi.org/10.2174/1871527314666150821103306
Nehilla BJ, Bergkvist M, Popat KC, Desai TA (2008) Purified and surfactant-free coenzyme Q10-loaded biodegradable nanoparticles. Int J Pharm 348:107–114. https://doi.org/10.1016/j.ijpharm.2007.07.001
Neroev VV, Archipova MM, Bakeeva LE, Fursova A, Grigorian EN, Grishanova AY et al (2008) Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 4. Age-related eye disease. SkQ1 returns vision to blind animals. Biochemistry (mosc) 73:1317–1328. https://doi.org/10.1134/s0006297908120043
NINDS (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664–671. https://doi.org/10.1212/01.wnl.0000201252.57661.e1
NINDS (2007) A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68:20–28. https://doi.org/10.1212/01.wnl.0000250355.28474.8e
Njus D, Kelley PM, Tu YJ, Schlegel HB (2020) Ascorbic acid: the chemistry underlying its antioxidant properties. Free Radic Biol Med 159:37–43. https://doi.org/10.1016/j.freeradbiomed.2020.07.013
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2010) Missing pieces in the Parkinson’s disease puzzle. Nat Med 16:653–661. https://doi.org/10.1038/nm.2165
Odunze IN, Klaidman LK, Adams JD Jr (1990) MPTP toxicity in the mouse brain and vitamin E. Neurosci Lett 108:346–349. https://doi.org/10.1016/0304-3940(90)90665-v
Offen D, Ziv I, Sternin H, Melamed E, Hochman A (1996) Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson’s disease. Exp Neurol 141:32–39. https://doi.org/10.1006/exnr.1996.0136
Olanow CW (2004) The scientific basis for the current treatment of Parkinson’s disease. Annu Rev Med 55:41–60. https://doi.org/10.1146/annurev.med.55.091902.104422
O’Malley Y, Fink BD, Ross NC, Prisinzano TE, Sivitz WI (2006) Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. J Biol Chem 281:39766–39775. https://doi.org/10.1074/jbc.M608268200
Ono K, Hasegawa K, Naiki H, Yamada M (2005) Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro. Biochem Biophys Res Commun 330:111–116. https://doi.org/10.1016/j.bbrc.2005.02.132
Pardo B, Mena MA, Fahn S, García de Yébenes J (1993) Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 8:278–284. https://doi.org/10.1002/mds.870080305
Parker WD Jr, Swerdlow RH (1998) Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet 62:758–762. https://doi.org/10.1086/301812
Parkinson Study Group (1998) Mortality in DATATOP: a multicenter trial in early Parkinson’s disease. Ann Neurol 43:318–325. https://doi.org/10.1002/ana.410430309
Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328:176–183. https://doi.org/10.1056/NEJM199301213280305
Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, Wall RA (1985) Partial protection from the dopaminergic neurotoxin Nmethyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett 60:109–114. https://doi.org/10.1016/0304-3940(85)90229-0
Philippens IH, Wubben JA, Finsen B, ’t Hart BA, (2013) Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model. J Neuroimmune Pharmacol 8(3):715–726. https://doi.org/10.1007/s11481-013-9450-z
Pileblad E, Magnusson T, Fornstedt B (1989) Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J Neurochem 52:978–980. https://doi.org/10.1111/j.1471-4159.1989.tb02550.x
Plotnikov EY, Zorov DB (2019) Pros and cons of use of mitochondria-targeted antioxidants. Antioxidants (Basel) 17:8(8):316. https://doi.org/10.3390/antiox8080316
Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF (2003) The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 66:1499–1503. https://doi.org/10.1016/s0006-2952(03)00504-5
Prasuhn J, Brüggemann N, Hessler N, Berg D, Gasser T, Brockmann K, Olbrich D, Ziegler A, König IR, Klein C, Kasten M (2019) An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial. Neurol Res Pract 1:31. https://doi.org/10.1186/s42466-019-0033-1
Pradhan P, Majhi O, Biswas A, Joshi VK, Sinha D (2020) Enhanced accumulation of reduced glutathione by Scopoletin improves survivability of dopaminergic neurons in Parkinson’s model. Cell Death Dis 11:739. https://doi.org/10.1038/s41419-020-02942-8
Pung YF, Rocic P, Murphy MP, Smith RA, Hafemeister J, Ohanyan V, Guarini G, Yin L, Chilian WM (2012) Resolution of mitochondrial oxidative stress rescues coronary collateral growth in Zucker obese fatty rats. Arterioscler Thromb Vasc Biol 32:325–334. https://doi.org/10.1161/ATVBAHA.111.241802
Richie JP, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE (2015) Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr 54:251–263. https://doi.org/10.1007/s00394-014-0706-z
Rodriguez-Cuenca S, Cocheme HM, Logan A, Abakumova I, Prime TA, Rose C et al (2010) Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med 48:161–172. https://doi.org/10.1016/j.freeradbiomed.2009.10.039
Ross MF, Kelso GF, Blaikie FH, James AM, Cocheme HM, Filipovska A, Da Ros T, Hurd TR, Smith RA, Murphy MP (2005) Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (mosc) 70:222–230. https://doi.org/10.1007/s10541-005-0104-5
Rotermund C, Truckenmüller FM, Schell H, Kahle PJ (2014) Diet-induced obesity accelerates the onset of terminal phenotypes in α-synuclein transgenic mice. J Neurochem 131:848–858. https://doi.org/10.1111/JNC.12813
Samuni Y, Goldstein S, Dean OM, Berk M (2013) The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 1830:4117–4129. https://doi.org/10.1016/j.bbagen.2013.04.016
Scheider WL, Hershey LA, Vena JE, Holmlund T, Marshall JR, Freudenheim JL (1997) Dietary antioxidants and other dietary factors in the etiology of Parkinson’s disease. Mov Disord 12:190–196. https://doi.org/10.1002/mds.870120209
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D et al (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65:716–723. https://doi.org/10.1001/archneur.2008.65.6.nct70003
Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ et al (2019) Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology 93:e1328–e1338. https://doi.org/10.1212/WNL.0000000000008194
Seaton TA, Jenner P, Marsden CD (1996) Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. J Neural Transm 103:315–329. https://doi.org/10.1007/BF01271243
Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G (1996) Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 20:1159–1170. https://doi.org/10.1016/s0278-5846(96)00103-0
Seidl SE, Potashkin JA (2011) The promise of neuroprotective agents in Parkinson’s disease. Front Neurol 2:68. https://doi.org/10.3389/fneur.2011.00068
Seidl SE, Santiago JA, Bilyk H, Potashkin JA (2014) The emerging role of nutrition in Parkinson’s disease. Front Aging Neurosci 6. https://doi.org/10.3389/FNAGI.2014.00036
Sharma A, Kaur P, Kumar V, Gill KD (2007) Attenuation of 1-methyl-4-phenyl-1, 2,3,6- tetrahydropyridine induced nigro-striatal toxicity in mice by N-acetyl cysteine. Cell Mol Biol 53:48–55. https://pubmed.ncbi.nlm.nih.gov/17519111/
Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT (2003) Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci 23:10756–10764. https://doi.org/10.1523/JNEUROSCI.23-34-10756.2003
Sheu SS, Nauduri D, Anders MW (2006) Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta 1762:256–265. https://doi.org/10.1016/j.bbadis.2005.10.007
Shults CW, Haas RH, Beal MF (1999) A possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s disease. BioFactors 9(2–4):267–272. https://doi.org/10.1002/biof.5520090223
Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S et al (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541–1550. https://doi.org/10.1001/archneur.59.10.1541
Shults CW (2003) Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 10:1917–1921. https://doi.org/10.2174/0929867033456882
Shults CW, Beal MF, Song D, Fontaine D (2004) Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp Neurol 188:491–494. https://doi.org/10.1016/j.expneurol.2004.05.003
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348–355. https://doi.org/10.1002/ana.410360305
Skulachev MV, Antonenko YN, Anisimov VN, Chernyak BV, Cherepanov DA, Chistyakov VA (2011) Mitochondrial-targeted plastoquinone derivatives. Effect on senescence and acute age-related pathologies. Curr Drug Targets 12:800–826. https://doi.org/10.2174/138945011795528859
Smith RA, Murphy MP (2011) Mitochondria-targeted antioxidants as therapies. Discov Med 11:106–114. https://pubmed.ncbi.nlm.nih.gov/21356165/
Smith RA, Porteous CM, Coulter CV, Murphy MP (1999) Selective targeting of an antioxidant to mitochondria. Eur J Biochem 263:709–716. https://doi.org/10.1046/j.1432-1327.1999.00543.x
Smith RA, Porteous CM, Gane AM, Murphy MP (2003) Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci USA 100:5407–5412. https://doi.org/10.1073/pnas.0931245100
Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O’Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM (2010) A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disord 25:1670–1674. https://doi.org/10.1002/mds.23148
Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S (2005) Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by coenzyme Q10. Neurobiol Dis 18:618–627. https://doi.org/10.1016/j.nbd.2004.10.021
Solesio ME, Prime TA, Logan A, Murphy MP, Del Mar A-J, Jordan J, Galindo MF (2013) The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson’s disease. Biochim Biophys Acta 1832:174–182. https://doi.org/10.1016/j.bbadis.2012.07.009
Szeto HH (2006) Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J 8(3):E521–E531. https://doi.org/10.1208/aapsj080362
Szeto HH (2008) Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal 10:601–619. https://doi.org/10.1089/ars.2007.1892
Tanner CM (2003) Is the cause of Parkinson’s disease environmental or hereditary?. Evidence from twin studies. Adv Neurol 91:133–142. https://pubmed.ncbi.nlm.nih.gov/12442672/
Taylor KSM, Cook JA, Counsell CE (2007) Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry 78:905–906. https://doi.org/10.1136/JNNP.2006.104695
Trnka J, Blaikie FH, Smith RA, Murphy MP (2008) A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. Free Radic Biol Med 44:1406–1419. https://doi.org/10.1016/j.freeradbiomed.2007.12.036
Ursini F, Bindoli A (1987) The role of selenium peroxidases in the protection against oxidative damage of membranes. Chem Phys Lipids 44:255–276. https://doi.org/10.1016/0009-3084(87)90053-3
Van Den Eeden SK, Tanner CM, Bernstein AL et al (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022. https://doi.org/10.1093/AJE/KWG068
Watanabe H, Hattori T, Kume A, Misu K, Ito T, Koike Y et al (2020) Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine. Medicine (baltimore) 99(35):e21576. https://doi.org/10.1097/MD.0000000000021576
Weber CA, Ernst ME (2006) Antioxidants, supplements, and Parkinson’s disease. Ann Pharmacother 40:935–938. https://doi.org/10.1345/aph.1G551
Werner CJ, Heyny-von Haussen R, Mall G, Wolf S (2008) Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci 6:8. https://doi.org/10.1186/1477-5956-6-8
Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A (2007) Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 166:561–567. https://doi.org/10.1093/aje/kwm127
Witschi A, Reddy S, Stofer B, Lauterburg BH (1992) The systemic availability of oral glutathione. Eur J Clin Pharmacol 43:667–669. https://doi.org/10.1007/BF02284971
Wolters E (2009) Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl. 3):S6–S12. https://doi.org/10.1016/S1353-8020(09)70770-9
Wright Willis A, Evanoff BA, Lian M et al (2010) Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 34:143–151. https://doi.org/10.1159/000275491
Wu Y, Yao Q, Jiang GX, Wang G, Cheng Q (2020) Identification of distinct blood-based biomarkers in early stage of Parkinson’s disease. Neurol Sci 41:893–901. https://doi.org/10.1007/s10072-019-04165-y
Xi Y, Feng D, Tao K, Wang R, Shi Y, Qin H, Murphy MP, Yang Q, Zhao G (2018) MitoQ protects dopaminergic neurons in a 6-OHDA induced PD model by enhancing Mfn2-dependent mitochondrial fusion via activation of PGC-1α. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease 1864(9):2859–2870. https://doi.org/10.1016/j.bbadis.2018.05.018
Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF (2009a) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J Neurochem 109:1427–1439. https://doi.org/10.1111/j.1471-4159.2009.06074.x
Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF (2009b) Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal 11:2095–2104. https://doi.org/10.1089/ars.2009.2445
Ying AF, Khan S, Wu Y, Jin A, Wong ASY, Tan EK, Yuan JM, Koh WP, Tan LCS (2020) Dietary antioxidants and risk of Parkinson’s disease in the Singapore Chinese Health Study. Mov Disord 35(10):1765–1773. https://doi.org/10.1002/mds.28173
Yoritaka A, Kawajiri S, Yamamoto Y, Nakahara T, Ando M, Hashimoto K, Nagase M, Saito Y, Hattori N (2015) Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson’s disease. Parkinsonism Relat Disord 21:911–916. https://doi.org/10.1016/j.parkreldis.2015.05.022
Yuneva AO, Kramarenko GG, Vetreshchak TV, Gallant S, Boldyrev AA (2002) Effect of carnosine on Drosophila melanogaster lifespan. Bull Exp Biol Med 133:559–561. https://doi.org/10.1023/a:1020273506970
Zhang D, Jiang H, Xie J (2014a) Alcohol intake and risk of Parkinson’s disease: a meta-analysis of observational studies. Mov Disord 29:819–822. https://doi.org/10.1002/MDS.25863
Zhang N, Shu HY, Huang T, Zhang QL, Li D, Zhang GQ, Peng XY, Liu CF, Luo WF, Hu LF (2014b) Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS ONE 9(6):e100286. https://doi.org/10.1371/journal.pone.0100286
Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, Ascherio A (2002) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59:1161–1169. https://doi.org/10.1212/01.wnl.0000028688.75881.12
Zhao K, Luo G, Zhao GM, Schiller PW, Szeto HH (2003) Transcellular transport of a highly polar 3+net charge opioid tetrapeptide. J Pharmacol Exp Ther 304:425–432. https://doi.org/10.1124/jpet.102.040147
Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH (2004) Cell permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 279:34682–34690. https://doi.org/10.1074/jbc.M402999200
Zhu TG, Wang XX, Luo WF, Zhang QL, Huang TT, Xu XS, Liu CF (2012) Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci Lett 506:175–179. https://doi.org/10.1016/j.neulet.2011.10.075
Author information
Authors and Affiliations
Contributions
Dr. Arpan Kumar Maiti conceived the idea for the review. All authors performed the literature search and helped in drafting the final version.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Banerjee, P., Saha, I., Sarkar, D. et al. Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review. Neurotox Res 40, 847–873 (2022). https://doi.org/10.1007/s12640-022-00501-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-022-00501-x